171 related articles for article (PubMed ID: 37754507)
41. Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas.
Le Page C; Chung J; Rahimi K; Köbel M; Provencher D; Mes-Masson AM
Curr Drug Targets; 2020; 21(10):974-995. PubMed ID: 31622218
[TBL] [Abstract][Full Text] [Related]
42. Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.
Bizzaro F; Falcetta F; D'Agostini E; Decio A; Minoli L; Erba E; Alessandro Peccatori F; Scanziani E; Colombo N; Zucchetti M; Bani MR; Ubezio P; Giavazzi R
Int J Cancer; 2018 Nov; 143(9):2187-2199. PubMed ID: 29752717
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
Garcia Garcia Y; de Juan Ferré A; Mendiola C; Barretina-Ginesta MP; Gaba Garcia L; Santaballa Bertrán A; Bover Barcelo I; Gil-Martin M; Manzano A; Rubio Pérez MJ; Romeo Marin M; Arqueros Núñez C; García-Martínez E; Gonzalez Martin A
Int J Gynecol Cancer; 2019 Jul; 29(6):1050-1056. PubMed ID: 31263024
[TBL] [Abstract][Full Text] [Related]
44. Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.
Petrillo M; Paris I; Vizzielli G; Amadio G; Cosentino F; Salutari V; Scambia G; Fagotti A
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S952-8. PubMed ID: 26036187
[TBL] [Abstract][Full Text] [Related]
45. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.
Murumägi A; Ungureanu D; Khan S; Arjama M; Välimäki K; Ianevski A; Ianevski P; Bergström R; Dini A; Kanerva A; Koivisto-Korander R; Tapper J; Lassus H; Loukovaara M; Mägi A; Hirasawa A; Aoki D; Pietiäinen V; Pellinen T; Bützow R; Aittokallio T; Kallioniemi O
Br J Cancer; 2023 Feb; 128(4):678-690. PubMed ID: 36476658
[TBL] [Abstract][Full Text] [Related]
46. Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan.
Kang JH; Lai YL; Cheng WF; Kim HS; Kuo KT; Chen YL; Lee YY
Sci Rep; 2020 Nov; 10(1):20012. PubMed ID: 33203969
[TBL] [Abstract][Full Text] [Related]
47. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.
Sehouli J; Braicu EI; Richter R; Denkert C; Jank P; Jurmeister PS; Kunze CA; Budczies J; Darb-Esfahani S; Schmitt WD; Traut A; Grabowski J; Taube ET; Plett H
Hum Pathol; 2019 Mar; 85():299-308. PubMed ID: 30428389
[TBL] [Abstract][Full Text] [Related]
48. Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
duPont NC; Enserro D; Brady MF; Moxley K; Walker JL; Cosgrove C; Bixel K; Tewari KS; Thaker P; Wahner Hendrickson AE; Rubin S; Fujiwara K; Casey AC; Soper J; Burger RA; Monk BJ
Gynecol Oncol; 2022 Feb; 164(2):398-405. PubMed ID: 34857397
[TBL] [Abstract][Full Text] [Related]
49. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
Konstantinopoulos PA; Cheng SC; Wahner Hendrickson AE; Penson RT; Schumer ST; Doyle LA; Lee EK; Kohn EC; Duska LR; Crispens MA; Olawaiye AB; Winer IS; Barroilhet LM; Fu S; McHale MT; Schilder RJ; Färkkilä A; Chowdhury D; Curtis J; Quinn RS; Bowes B; D'Andrea AD; Shapiro GI; Matulonis UA
Lancet Oncol; 2020 Jul; 21(7):957-968. PubMed ID: 32553118
[TBL] [Abstract][Full Text] [Related]
50. A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ; Swart AM; Pfisterer J; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Kurzeder C; du Bois A; Sehouli J; Kimmig R; Stähle A; Collinson F; Essapen S; Gourley C; Lortholary A; Selle F; Mirza MR; Leminen A; Plante M; Stark D; Qian W; Parmar MK; Oza AM;
N Engl J Med; 2011 Dec; 365(26):2484-96. PubMed ID: 22204725
[TBL] [Abstract][Full Text] [Related]
51. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
[TBL] [Abstract][Full Text] [Related]
52. The Role of Systematic Lymphadenectomy in Low-Grade Serous Ovarian Cancer: A Systematic Review and Meta-Analysis.
Montero-Macías R; Segura-Sampedro JJ; Rigolet P; Lecuru F; Craus-Miguel A; Castillo-Tuñón JM
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473315
[TBL] [Abstract][Full Text] [Related]
53. The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction.
Johnson RL; Laios A; Jackson D; Nugent D; Orsi NM; Theophilou G; Thangavelu A; de Jong D
J Clin Med; 2021 Dec; 10(24):. PubMed ID: 34945222
[TBL] [Abstract][Full Text] [Related]
54. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
[TBL] [Abstract][Full Text] [Related]
55. Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers.
Di Lorenzo P; Conteduca V; Scarpi E; Adorni M; Multinu F; Garbi A; Betella I; Grassi T; Bianchi T; Di Martino G; Amadori A; Maniglio P; Strada I; Carinelli S; Jaconi M; Aletti G; Zanagnolo V; Maggioni A; Savelli L; De Giorgi U; Landoni F; Colombo N; Fruscio R
Front Oncol; 2022; 12():970918. PubMed ID: 36237308
[TBL] [Abstract][Full Text] [Related]
56. Redefining the standard of care for low-grade serous ovarian cancer.
Manning-Geist BL; Cantor T; O'Cearbhaill RE; Grisham RN
Clin Adv Hematol Oncol; 2024 Jun; 22(5):205-226. PubMed ID: 38805312
[TBL] [Abstract][Full Text] [Related]
57. Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
Mert I; Chhina J; Allo G; Dai J; Seward S; Carey MS; Llaurado M; Giri S; Rattan R; Munkarah AR
Gynecol Oncol; 2017 Aug; 146(2):319-326. PubMed ID: 28545687
[TBL] [Abstract][Full Text] [Related]
58. Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer.
Andrikopoulou A; Liontos M; Skafida E; Koutsoukos K; Apostolidou K; Kaparelou M; Rouvalis A; Bletsa G; Dimopoulos MA; Zagouri F
Int J Gynecol Cancer; 2023 Apr; 33(4):571-576. PubMed ID: 36604119
[TBL] [Abstract][Full Text] [Related]
59. Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial).
Marth C; Abreu MH; Andersen KK; Aro KM; de Lurdes Batarda M; Boll D; Ekmann-Gade AW; Haltia UM; Hansen J; Haug AJ; Høgdall C; Korach J; Lassus H; Lindemann K; Van Nieuwenhuysen E; Ottevanger PB; Polterauer S; Schnack TH
Cancer; 2022 Aug; 128(16):3080-3089. PubMed ID: 35714310
[TBL] [Abstract][Full Text] [Related]
60. [Cytopathological characterization of ascites for the diagnosis of serous ovarian carcinoma].
Chang YH; Zou BQ; Cai Y; Yang SD; Zhang Y; Liang JB; Li C
Zhonghua Zhong Liu Za Zhi; 2023 May; 45(5):424-432. PubMed ID: 37188628
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
